Business Standard

Monday, January 06, 2025 | 06:36 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Serum Institute of India gets nod to resume Covid-19 vaccine trial

The resumption of trails was allowed after the vaccine maker submitted recommendations of the Data Safety Monitoring Board (DSMB), the UK, and DSMB, India

Vaccine, Covid
Premium

AstraZeneca resumed clinical trials in the UK last weekend after Medicines and Healthcare Products Regulatory Agency (MHRA) dubbed them “safe”

Sohini Das Mumbai
The country's drug regulator on Tuesday allowed Serum Institute of India (SII) to resume trials of the AstraZeneca-Oxford vaccine candidate, Covishield, revoking its earlier order suspending new recruitments for phase two and three tests.
 
The resumption of trails was allowed after the vaccine maker submitted recommendations of the Data Safety Monitoring Board (DSMB), the UK, and DSMB, India. Giving permission, Drugs Controller General of India (DCGI) V G Somani said that SII’s reply had been "carefully examined".
 
The regulator, earlier, had asked SII to suspend volunteer recruitments for phase two and three clinical trials of Covishield and directed the firm

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in